<DOC>
	<DOCNO>NCT02567682</DOCNO>
	<brief_summary>The purpose study evaluate effect concomitant administration GBT440 caffeine ( CYP1A2 probe substrate ) , S warfarin ( CYP2C9 probe substrate ) , omeprazole ( CYP2C19 probe substrate ) , midazolam ( CYP3A4 probe substrate ) plasma concentration .</brief_summary>
	<brief_title>Drug Interaction Study GBT440 With Caffeine , S-warfarin , Omeprazole , Midazolam Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subject female nonchildbearing potential male , healthy , nonsmoking , 18 55 year old , inclusive , screen Male subject agree use contraception Willing able give write informed consent Evidence history clinically significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History hypersensitivity allergy drug , food , substance History presence abnormal electrocardiogram hypertension History alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction within 1 year screening Participated another clinical trial investigational drug within 30 day ( 5 halflives investigational drug , whichever long ) prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>anemia , sickle cell</keyword>
</DOC>